Fondaparinux sodium - Sanofi aventis
Alternative Names: Arixtra; GSK 576428; ORG 31540; Quixidar; SR 90107; SR 90107A; XantidarLatest Information Update: 05 Nov 2023
At a glance
- Originator sanofi-aventis
- Developer GSK
- Class Anticoagulants; Antithrombotics; Polysaccharides
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute coronary syndromes; Deep vein thrombosis; Myocardial infarction; Pulmonary embolism; Thromboembolism; Unstable angina pectoris; Venous thrombosis